The basic science underlying antiangiogenic therapies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1378, Issue 2, 1998, Pages

  Rundell, Kathleen ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPEPTIN BLOCKING AGENT; ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; ENDOSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; CONFERENCE PAPER; DRUG MECHANISM; DRUG RESISTANCE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PREDICTION; PRIORITY JOURNAL; STEADY STATE;

ANIMALIA;

EID: 0032517380     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(98)00021-3     Document Type: Conference Paper

References (13)

1. [1] T. Boehm, J. Folkman, T. Browder, M.S. O'Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature 390 (1997) 404-407.
2. [2] P. Borgstrom, M.A. Bourdon, K.J. Hillan, P. Sriramarao, N. Ferrara, Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo, Prostate 35 (1998) 1-10.
3. [3] N. Bouck, V. Stellmach, S.C. Hsu, How tumors become angiogenic, Adv. Cancer Res. 69 (1996) 135-174.
4. [4] P.C. Brooks, S. Silletti, T.L. von Schalscha, M. Friedlander, D.A. Cheresh, Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity, Cell 92 (1998) 391-400.
5. [5] S. Gately, P. Twardowski, M.S. Stack, D.L. Cundiff, D. Grella, F.J. Castellino, J. Enghild, H.C. Kwaan, F. Lee, R.A. Kramer, O. Volpert, N. Bouck, G.A. Soff, The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin, Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10868-10872.
6. [6] C.K. Goldman, R.L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G.Y. Gillespie, G.P. Siegal, X. Mao, A.J. Bett, W.R. Huckle, K.A. Thomas, D.T. Curiel, Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate, Proc. Natl. Acad. Sci. U.S.A. (in press).
7. [7] D. Hanahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86 (1996) 353-364.
8. [8] T.I. Koblizek, C. Weiss, G.D. Yancopoulos, U. Deutsch, W. Risau, Angiopoietin-1 induces sprouting angiogenesis in vitro, Curr. Biol. 8 (1998) 529-532.
9. [9] P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T.H. Aldrich, N. Papadopoulos, T.J. Daly, S. Davis S, T.N. Sato, G.D. Yancopoulos, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science 277 (1997) 55-60.
10. [10] S. Parangi, M. O'Reilly, G. Christofori, L. Holmgren, J. Grosfeld, J. Folkman, D. Hanahan, Antiangiogenic therapy of transgenic mice impairs de novo tumor growth, Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2002-2007.
11. [11] K.G. Peters, A. Coogan, D. Berry, J. Marks, J.D. Inglehart, C.D. Kontos, P. Rao, S. Sankar, E. Trogan, Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis, Br. J. Cancer 77 (1998) 51-56.
12. [12] C.D. Pham, T.P. Roberts, N. van Bruggen, O. Melnyk, J. Mann, N. Ferrara, R.L. Cohen, R.C. Brasch, Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor, Cancer Invest. 16 (1998) 225-230.
13. [13] G.D. Yancopoulos, M. Klagsbrun, J. Folkman, Vasculogenesis, angiogenesis and growth factors: Epfrins enter the fray at the border, Cell 93 (1998) 661-664.